Edwards Lifesciences Corporation $EW Shares Bought by AIA Group Ltd

AIA Group Ltd grew its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 7.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 137,043 shares of the medical research company’s stock after buying an additional 10,083 shares during the quarter. AIA Group Ltd’s holdings in Edwards Lifesciences were worth $10,974,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Brighton Jones LLC purchased a new position in Edwards Lifesciences in the 4th quarter valued at about $266,000. NewEdge Advisors LLC increased its stake in Edwards Lifesciences by 8.1% during the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock worth $2,787,000 after buying an additional 2,665 shares in the last quarter. Sei Investments Co. raised its holdings in shares of Edwards Lifesciences by 16.7% during the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after acquiring an additional 58,988 shares during the last quarter. Squarepoint Ops LLC raised its holdings in shares of Edwards Lifesciences by 277.7% during the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock valued at $5,417,000 after acquiring an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina lifted its position in shares of Edwards Lifesciences by 0.4% in the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock valued at $21,028,000 after acquiring an additional 1,065 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $91.70, for a total transaction of $56,762.30. Following the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at $3,671,117.80. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the transaction, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 45,577 shares of company stock worth $3,855,527. Insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on EW. Robert W. Baird lifted their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. Mizuho increased their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday. TD Cowen reissued a “buy” rating and issued a $104.00 price objective (up from $97.00) on shares of Edwards Lifesciences in a research note on Tuesday, June 2nd. Barclays restated an “overweight” rating and issued a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Finally, Royal Bank Of Canada lifted their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.95.

Edwards Lifesciences Stock Performance

NYSE EW opened at $85.72 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. The stock’s fifty day moving average is $87.34 and its two-hundred day moving average is $83.94. The firm has a market capitalization of $49.36 billion, a P/E ratio of 45.60, a price-to-earnings-growth ratio of 2.15 and a beta of 0.86. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The business had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The company’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period last year, the company earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.